Article

Genentech changes distribution channels for bevacizumab

San Francisco, CA-After meeting with eye specialists Monday, Genentech Inc. will consider reversing a decision to narrow the supply channels for its drug bevacizumab (Avastin).

San Francisco, CA-After meeting with eye specialists Monday, Genentech Inc. will consider reversing a decision to narrow the supply channels for its drug bevacizumab (Avastin).

First the Southern San Francisco-based biotech company needs FDA clearance to continue allowing wholesalers to sell the drug to compounding pharmacies.

The company is forbidden by the FDA to use bevacizumab for any unapproved purposes.

Currently Genentech has postponed the restriction on bevacizumab sales until January 2008 so physicians can find other ways to obtain the product. Discussion also will be continued with the American Academy of Ophthalmology (AAO) and the American Society of Retina Specialists.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.